Page last updated: 2024-11-04

vorinostat and Adrenal Cancer

vorinostat has been researched along with Adrenal Cancer in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Smeltzer, JP1
Viswanatha, DS1
Habermann, TM1
Patnaik, MM1

Other Studies

1 other study available for vorinostat and Adrenal Cancer

ArticleYear
Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.
    American journal of hematology, 2012, Volume: 87, Issue:9

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Humans; Hydro

2012